BPC-157 for Rotator Cuff Injuries: What the Research Shows

The rotator cuff — four muscles and tendons (supraspinatus, infraspinatus, subscapularis, teres minor) — stabilizes the shoulder. Injuries range from tendonitis to complete tears. Rotator cuff tendons heal poorly due to limited blood supply, particularly in the supraspinatus "critical zone."

BPC-157 targets several rotator cuff healing factors:

• Tendon-to-Bone Healing: Specifically studied for the tendon-bone interface
• Angiogenesis: Addresses the critical zone's poor vascularity
• Collagen Organization: Improves alignment and strength of healing fibers
• Inflammation Modulation: Reduces excessive inflammation while supporting healing

Direct rotator cuff research:

• Chang et al., 2011: BPC-157 significantly improved tendon-to-bone healing with better histological scores and biomechanical strength.
• Supraspinatus Studies: Improved healing after detachment and reattachment in animal models.
• Supporting Data: Extensive Achilles and patellar tendon research supports general tendon-healing capability.

Evidence quality: Directly relevant rotator cuff animal data. Lack of human trials is the key limitation.

• Dosage: 250–500 mcg per day
• Injection: Subcutaneous near the shoulder (deltoid area)
• Frequency: Once or twice daily
• Duration: 6–12 weeks (rotator cuff healing is inherently slow)

• Week 1–2: Reduced shoulder pain and inflammation
• Week 3–4: Improved range of motion and less night pain
• Week 6–8: Functional improvement; easier daily activities
• Week 8–12: Significant healing; tissue remodeling continues

Physical therapy and gradual loading are essential.

Ascension Peptides is our recommended source for research-grade BPC-157:

• Third-party tested with ≥98% HPLC purity
• Published Certificates of Analysis for every batch
• US-based with reliable shipping

Always verify that your supplier provides current third-party testing documentation.